Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
TipRanks (Fri, 22-May 12:33 PM ET)
Market Chameleon (Wed, 6-May 4:47 AM ET)
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
Globe Newswire (Wed, 6-May 8:30 AM ET)
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Globe Newswire (Mon, 4-May 4:30 PM ET)
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Globe Newswire (Tue, 7-Apr 8:00 AM ET)
Legendary Investors are Rotating Capital into AI Powered Biotech
Globe Newswire (Mon, 30-Mar 9:15 AM ET)
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
Globe Newswire (Wed, 11-Mar 7:00 AM ET)
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
Globe Newswire (Tue, 10-Mar 7:00 AM ET)
Market Chameleon (Thu, 20-Nov 3:25 AM ET)
Market Chameleon (Fri, 10-Oct 4:11 AM ET)
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.
As of May 27, 2026, CRSP stock price climbed to $53.53 with 1,764,422 million shares trading.
CRSP has a beta of 1.95, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.18 to the broad based SPY ETF.
CRSP has a market cap of $5.16 billion. This is considered a Mid Cap stock.
Last quarter Crispr Therapeutics Ag - Common Shares reported $1 million in Revenue and -$1.28 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.06.
In the last 3 years, CRSP traded as high as $91.10 and as low as $30.04.
The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKK, IWM, XBI, ARKG, VXF.
CRSP has outperformed the market in the last year with a return of +45.2%, while the SPY ETF gained +30.9%. However, in the most recent history, CRSP shares have underperformed the stock market with its stock returning -13.3% in the last 3 month period and +1.3% for the last 2 week period, while SPY has returned +9.1% and +1.7%, respectively.
CRSP support price is $49.65 and resistance is $53.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.